 Xeris Biopharma Holdings NASDAQ:XERS Inc revealed the results of the extended evaluation of levoketoconazole, or Recorlev, from the Phase 3 SONICS study published in the European Journal of Endocrinology. The study evaluated longer-term effects of Recorlev on cortisol levels, biomarkers of Cushings syndrome CS comorbidities, clinical signs and symptoms of CS, and quality of life. 